Details of the Drug

General Information of Drug (ID: DMHL7OB)

Drug Name

Uracil mustard

Synonyms

Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Approved	[1]
Chronic myelogenous leukaemia	2A20.0	Approved	[2]
Polycythemia vera	2A20.4	Approved	[2]
Small lymphocytic lymphoma	2A82.0	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

252.09

Logarithm of the Partition Coefficient (xlogp)

0.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cell death	Not Available	PARP1	OTIESHK4	[3]
Metabolism and nutrition disorders	Not Available	ART1	OT7FBG5W	[3]
Skin and subcutaneous tissue disorders	Not Available	IL1B	OT0DWXXB	[3]
Skin and subcutaneous tissue disorders	Not Available	CSF2	OT1M7D28	[3]
Skin and subcutaneous tissue disorders	Not Available	IL6	OTUOSCCU	[3]
-----------

Chemical Identifiers

Formula: C8H11Cl2N3O2
IUPAC Name: 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione
Canonical SMILES: C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl
InChI: InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)
InChIKey: IDPUKCWIGUEADI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 6194
ChEBI ID: CHEBI:9884
CAS Number: 66-75-1
DrugBank ID: DB00791
TTD ID: D0J9UN

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1)	OT7FBG5W	NAR1_HUMAN	Drug Response	[3]
Granulocyte-macrophage colony-stimulating factor (CSF2)	OT1M7D28	CSF2_HUMAN	Drug Response	[3]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Drug Response	[3]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Drug Response	[3]
Poly polymerase 1 (PARP1)	OTIESHK4	PARP1_ARATH	Drug Response	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Uracil mustard (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Uracil mustard and Roflumilast.	Asthma [CA23]	[5]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Uracil mustard due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[6]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Uracil mustard due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[6]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Uracil mustard due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[6]
ABT-492	DMJFD2I	Minor	Decreased absorption of Uracil mustard due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[6]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Uracil mustard due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[6]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Uracil mustard and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[7]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Uracil mustard and Denosumab.	Low bone mass disorder [FB83]	[8]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Uracil mustard and Tecfidera.	Multiple sclerosis [8A40]	[9]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Uracil mustard and Siponimod.	Multiple sclerosis [8A40]	[7]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Uracil mustard and Fingolimod.	Multiple sclerosis [8A40]	[10]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Uracil mustard and Ocrelizumab.	Multiple sclerosis [8A40]	[11]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Uracil mustard and Ozanimod.	Multiple sclerosis [8A40]	[5]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Uracil mustard and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[12]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Uracil mustard due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[6]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Uracil mustard and Canakinumab.	Rheumatoid arthritis [FA20]	[13]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Uracil mustard and Rilonacept.	Rheumatoid arthritis [FA20]	[13]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Uracil mustard and Golimumab.	Rheumatoid arthritis [FA20]	[14]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Uracil mustard and Leflunomide.	Rheumatoid arthritis [FA20]	[15]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Uracil mustard when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[16]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Uracil mustard and Azathioprine.	Transplant rejection [NE84]	[7]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Uracil mustard and Plazomicin.	Urinary tract infection [GC08]	[7]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Uracil mustard and Ganciclovir.	Virus infection [1A24-1D9Z]	[7]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Uracil mustard and Valganciclovir.	Virus infection [1A24-1D9Z]	[7]
-----------


⏷ Show the Full List of 24 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
2	Uracil mustard FDA Label
3	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
4	Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
5	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
7	Cerner Multum, Inc. "Australian Product Information.".
8	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
9	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
10	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
11	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
12	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
13	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
14	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
15	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
16	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]